CN101039914A - 作为激酶抑制剂的三氟甲基取代的苯甲酰胺化合物 - Google Patents

作为激酶抑制剂的三氟甲基取代的苯甲酰胺化合物 Download PDF

Info

Publication number
CN101039914A
CN101039914A CNA200580034662XA CN200580034662A CN101039914A CN 101039914 A CN101039914 A CN 101039914A CN A200580034662X A CNA200580034662X A CN A200580034662XA CN 200580034662 A CN200580034662 A CN 200580034662A CN 101039914 A CN101039914 A CN 101039914A
Authority
CN
China
Prior art keywords
methyl
formula
phenyl
trifluoromethyl
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200580034662XA
Other languages
English (en)
Chinese (zh)
Inventor
G·卡拉瓦蒂
P·菲雷
P·因巴赫
G·马蒂尼-巴伦
L·B·佩雷斯
T·圣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101039914A publication Critical patent/CN101039914A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNA200580034662XA 2004-08-11 2005-08-10 作为激酶抑制剂的三氟甲基取代的苯甲酰胺化合物 Pending CN101039914A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0417905.7 2004-08-11
GBGB0417905.7A GB0417905D0 (en) 2004-08-11 2004-08-11 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910175026A Division CN101696188A (zh) 2004-08-11 2005-08-10 作为激酶抑制剂的三氟甲基取代的苯甲酰胺化合物

Publications (1)

Publication Number Publication Date
CN101039914A true CN101039914A (zh) 2007-09-19

Family

ID=33017336

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200580034662XA Pending CN101039914A (zh) 2004-08-11 2005-08-10 作为激酶抑制剂的三氟甲基取代的苯甲酰胺化合物
CN200910175026A Pending CN101696188A (zh) 2004-08-11 2005-08-10 作为激酶抑制剂的三氟甲基取代的苯甲酰胺化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910175026A Pending CN101696188A (zh) 2004-08-11 2005-08-10 作为激酶抑制剂的三氟甲基取代的苯甲酰胺化合物

Country Status (17)

Country Link
US (2) US20080096883A1 (cg-RX-API-DMAC10.html)
EP (1) EP1778640A1 (cg-RX-API-DMAC10.html)
JP (1) JP2008509187A (cg-RX-API-DMAC10.html)
KR (1) KR20070046851A (cg-RX-API-DMAC10.html)
CN (2) CN101039914A (cg-RX-API-DMAC10.html)
AU (1) AU2005270313A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0514288A (cg-RX-API-DMAC10.html)
CA (1) CA2575316A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP077235A (cg-RX-API-DMAC10.html)
GB (1) GB0417905D0 (cg-RX-API-DMAC10.html)
IL (1) IL181169A0 (cg-RX-API-DMAC10.html)
MA (1) MA28822B1 (cg-RX-API-DMAC10.html)
MX (1) MX2007001642A (cg-RX-API-DMAC10.html)
NO (1) NO20071300L (cg-RX-API-DMAC10.html)
RU (1) RU2007108861A (cg-RX-API-DMAC10.html)
TN (1) TNSN07048A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006015859A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675289A (zh) * 2011-03-18 2012-09-19 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的新型n-苯基苯甲酰胺衍生物
CN111904960A (zh) * 2020-05-19 2020-11-10 合肥合源药业有限公司 一种固体分散体及药用组合物

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054916A1 (en) † 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
EP1878727A4 (en) * 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
RU2452492C2 (ru) * 2006-04-05 2012-06-10 Новартис Аг КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
AU2007272533A1 (en) * 2006-07-13 2008-01-17 Novartis Ag Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
AU2007293065B2 (en) * 2006-09-05 2011-08-18 Amgen Inc. Phthalazine, AZA- and diaza-phthalazine compounds and methods of use
US20100173426A1 (en) * 2006-12-19 2010-07-08 Johnson Faye M Biomaker identifying the reactivation of stat3 after src inhibition
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
US8022085B2 (en) * 2007-05-07 2011-09-20 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
AU2008248073B2 (en) * 2007-05-07 2011-03-24 Amgen Inc. Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
US20100292292A1 (en) * 2007-09-13 2010-11-18 Link Medicine Corporation Treatment of Neurodegenerative Diseases Using Indatraline Analogs
US8367671B2 (en) * 2008-03-21 2013-02-05 Amgen Inc. Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
US20110039845A1 (en) 2008-04-23 2011-02-17 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
WO2010025201A1 (en) 2008-08-29 2010-03-04 Amgen Inc. Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases.
WO2010025202A1 (en) 2008-08-29 2010-03-04 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
US8497269B2 (en) 2008-10-10 2013-07-30 Amgen Inc. Phthalazine compounds as p38 map kinase modulators and methods of use thereof
US8772481B2 (en) 2008-10-10 2014-07-08 Amgen Inc. Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
CN102316738A (zh) * 2009-02-18 2012-01-11 盛泰萨路申有限公司 作为激酶抑制剂的酰胺类
EP2440053A4 (en) 2009-06-09 2012-10-31 California Capital Equity Llc BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
CA2765030C (en) 2009-06-09 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
WO2010144586A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
PH12012500809A1 (en) * 2009-10-30 2012-11-26 Ariad Pharma Inc Methods and compositions for treating cancer
EP2701507A1 (en) * 2011-04-26 2014-03-05 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
SG11201606876RA (en) 2015-03-04 2016-10-28 Gilead Sciences Inc Toll like receptor modulator compounds
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
KR102463217B1 (ko) * 2020-07-13 2022-11-07 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 4-아미노퀴나졸린-2-카복스아미드 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111925331A (zh) * 2020-07-14 2020-11-13 上海毕得医药科技有限公司 一种6-溴酞嗪的合成方法
CN122167728A (zh) * 2026-05-08 2026-06-09 苏州先觉生物科技有限公司 一种胶原拟肽及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6587829B1 (en) * 1997-07-31 2003-07-01 Schering Corporation Method and apparatus for improving patient compliance with prescriptions
US6523009B1 (en) * 1999-11-06 2003-02-18 Bobbi L. Wilkins Individualized patient electronic medical records system
US20030236682A1 (en) * 1999-11-08 2003-12-25 Heyer Charlette L. Method and system for managing a healthcare network
US6684276B2 (en) * 2001-03-28 2004-01-27 Thomas M. Walker Patient encounter electronic medical record system, method, and computer product
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675289A (zh) * 2011-03-18 2012-09-19 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的新型n-苯基苯甲酰胺衍生物
CN102675289B (zh) * 2011-03-18 2014-11-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物
CN111904960A (zh) * 2020-05-19 2020-11-10 合肥合源药业有限公司 一种固体分散体及药用组合物

Also Published As

Publication number Publication date
IL181169A0 (en) 2007-07-04
RU2007108861A (ru) 2008-09-20
NO20071300L (no) 2007-04-19
WO2006015859A1 (en) 2006-02-16
US20060035897A1 (en) 2006-02-16
BRPI0514288A (pt) 2008-06-10
MX2007001642A (es) 2007-04-10
GB0417905D0 (en) 2004-09-15
CA2575316A1 (en) 2006-02-16
KR20070046851A (ko) 2007-05-03
ECSP077235A (es) 2007-03-29
AU2005270313A1 (en) 2006-02-16
JP2008509187A (ja) 2008-03-27
EP1778640A1 (en) 2007-05-02
MA28822B1 (fr) 2007-08-01
TNSN07048A1 (en) 2008-06-02
CN101696188A (zh) 2010-04-21
US20080096883A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
CN1294135C (zh) 作为蛋白激酶抑制剂的吡咯并嘧啶
CN1083452C (zh) 抑制蛋白质酪氨酸激酶介导的细胞增殖的吡啶并[2,3-d]嘧啶
CN1902200A (zh) 用做蛋白激酶抑制剂的1h-咪唑并喹啉类衍生物
CN100345830C (zh) 稠合杂芳基衍生物
CN1240688C (zh) 喹唑啉化合物
CN1138778C (zh) 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途
CN1655788A (zh) 治疗蛋白激酶依赖性疾病的1H-咪唑并[4,5-c]喹啉衍生物
CN1882586A (zh) 用于治疗蛋白激酶依赖性疾病的1h-咪唑并[4,5-c]喹啉衍生物
CN1538847A (zh) 4-氨基-6-苯基-吡咯并[2,3-d]嘧啶衍生物
JP4917109B2 (ja) キナーゼ阻害剤としてのヘテロ二環式カルボキサミド
CN1094043A (zh) 喹唑啉衍生物
US20060035897A1 (en) Trifluoromethyl substituted benzamides as kinase inhibitors
CN1909908A (zh) 用于治疗蛋白激酶依赖性疾病的吡唑并[1,5-a]嘧啶-7-基-胺衍生物
CN1245402C (zh) 吲哚衍生物、其制备方法、含有它们的药物组合物及其用途
CN1422268A (zh) 5-烷基吡啶并[2,3-d]嘧啶酪氨酸激酶抑制剂
CN101065016A (zh) 蛋白激酶的抑制剂咪唑并[4,5-b]吡嗪酮
CN1636005A (zh) 苯并噻嗪酮和苯并噁嗪酮化合物
CN1395578A (zh) 吡啶并[2,3-d]嘧啶-2,7-二胺激酶抑制剂
CN1849325A (zh) 可抑制蛋白激酶的噻唑并、噁唑并和咪唑并喹唑啉化合物
CN101031560A (zh) 用作酪氨酸激酶抑制剂的环状二芳基脲
CN1960988A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN1860118A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN1212695A (zh) 4-氨基-嘧啶衍生物,含该化合物的药物制剂,其用途及其制造方法
CN1668610A (zh) 苯基-[4-(3-苯基-1h-吡唑-4-基)-嘧啶-2-基]-胺衍生物
CN1444563A (zh) 喹啉和喹唑啉衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070919